期刊
CURRENT PHARMACEUTICAL DESIGN
卷 14, 期 16, 页码 1615-1619出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161208784705423
关键词
blood-brain barrier; saturable transport; passive diffusion; urocortin; leptin; insulin; GALP; mahogany peptide
资金
- NIDDK NIH HHS [R56 DK054880, R01 DK054880-10, R01 DK054880, DK57880] Funding Source: Medline
- NINDS NIH HHS [R01 NS045751-06, NS45751, NS46528, R01 NS045751-04, R01 NS045751, R01 NS046528, R01 NS046528-05] Funding Source: Medline
The two main ways for peptides in the peripheral body to enter the brain are by either saturable transport or passive diffusion across the blood-brain barrier (BBB). Saturable transport systems have the advantage of being responsive to physiological and pathological stimuli. Since saturable systems can regulate peptide entry into the brain, they have the potential to play controlling roles in feeding behavior. For therapeutic applications, however, saturable systems have the disadvantage of functioning as a threshold to limit access of large amounts of peptides into the brain. This pharmacological problem presumably would not be encountered for peptides crossing the BBB by passive diffusion, a process dependent on physicochemical properties. Thus, the gatekeeper function of the BBB can be expanded to a primary governing role, especially for entry of ingestive peptides subject to their respective saturable transport systems.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据